Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

AIM: This study investigated the effects of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban (10 mg), an oral, direct Factor Xa inhibitor. METHOD: This single centre, non-randomized, non-blinded study included subjects with mild (n = 8) or moderate hepa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kubitza, Dagmar, Roth, Angelika, Becka, Michael, Alatrach, Abir, Halabi, Atef, Hinrichsen, Holger, Mueck, Wolfgang
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Science Inc 2013
Assuntos:
Pharmacokinetics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3703231/
https://ncbi.nlm.nih.gov/pubmed/23294275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12054
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares